Literature DB >> 21896780

Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression.

Young-Ho Ahn1, Yanan Yang, Don L Gibbons, Chad J Creighton, Fei Yang, Ignacio I Wistuba, Wei Lin, Nishan Thilaganathan, Cristina A Alvarez, Jonathon Roybal, Elizabeth J Goldsmith, Cathy Tournier, Jonathan M Kurie.   

Abstract

MAP2K4 encodes a dual-specificity kinase (mitogen-activated protein kinase kinase 4, or MKK4) that is mutated in a variety of human malignancies, but the biochemical properties of the mutant kinases and their roles in tumorigenesis have not been fully elucidated. Here we showed that 8 out of 11 cancer-associated MAP2K4 mutations reduce MKK4 protein stability or impair its kinase activity. On the basis of findings from bioinformatic studies on human cancer cell lines with homozygous MAP2K4 loss, we posited that MKK4 functions as a tumor suppressor in lung adenocarcinomas that develop in mice owing to expression of mutant Kras and Tp53. Conditional Map2k4 inactivation in the bronchial epithelium of mice had no discernible effect alone but increased the multiplicity and accelerated the growth of incipient lung neoplasias induced by oncogenic Kras. MKK4 suppressed the invasion and metastasis of Kras-Tp53-mutant lung adenocarcinoma cells. MKK4 deficiency increased peroxisomal proliferator-activated receptor γ2 (PPARγ2) expression through noncanonical MKK4 substrates, and PPARγ2 enhanced tumor cell invasion. We conclude that Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing PPARγ2 levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896780      PMCID: PMC3209326          DOI: 10.1128/MCB.05562-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

Review 1.  The many faces of PPARgamma.

Authors:  Michael Lehrke; Mitchell A Lazar
Journal:  Cell       Date:  2005-12-16       Impact factor: 41.582

2.  Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2.

Authors:  Lu Chen; Brian M Necela; Weidong Su; Masahiro Yanagisawa; Panos Z Anastasiadis; Alan P Fields; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2006-06-30       Impact factor: 5.157

3.  Somatic mutations of the protein kinase gene family in human lung cancer.

Authors:  Helen Davies; Chris Hunter; Raffaella Smith; Philip Stephens; Chris Greenman; Graham Bignell; Jon Teague; Adam Butler; Sarah Edkins; Claire Stevens; Adrian Parker; Sarah O'Meara; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Jody Clements; Jennifer Cole; Ed Dicks; Ken Edwards; Simon Forbes; Matthew Gorton; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathon Hinton; David Jones; Vivienne Kosmidou; Ross Laman; Richard Lugg; Andrew Menzies; Janet Perry; Robert Petty; Keiran Raine; Rebecca Shepherd; Alexandra Small; Helen Solomon; Yvonne Stephens; Calli Tofts; Jennifer Varian; Anthony Webb; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Anthony Green; Maggie Knowles; Suet Y Leung; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin T Teh; Siu T Yuen; Sunil R Lakhani; Douglas F Easton; Barbara L Weber; Peter Goldstraw; Andrew G Nicholson; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

4.  c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells.

Authors:  T S Khatlani; M Wislez; M Sun; H Srinivas; K Iwanaga; L Ma; A E Hanna; D Liu; L Girard; Y H Kim; J R Pollack; J D Minna; I I Wistuba; J M Kurie
Journal:  Oncogene       Date:  2006-10-23       Impact factor: 9.867

5.  K-ras activation generates an inflammatory response in lung tumors.

Authors:  H Ji; A M Houghton; T J Mariani; S Perera; C B Kim; R Padera; G Tonon; K McNamara; L A Marconcini; A Hezel; N El-Bardeesy; R T Bronson; D Sugarbaker; R S Maser; S D Shapiro; K-K Wong
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

6.  Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo.

Authors:  Harumi Shimizu; David Saliba; Maura Wallace; Lee Finlan; Patrick R R Langridge-Smith; Ted R Hupp
Journal:  Biochem J       Date:  2006-07-15       Impact factor: 3.857

7.  Distinguishing cancer-associated missense mutations from common polymorphisms.

Authors:  Joshua S Kaminker; Yan Zhang; Allison Waugh; Peter M Haverty; Brock Peters; Dragan Sebisanovic; Jeremy Stinson; William F Forrest; J Fernando Bazan; Somasekar Seshagiri; Zemin Zhang
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

8.  Signatures of mutation and selection in the cancer genome.

Authors:  Graham R Bignell; Chris D Greenman; Helen Davies; Adam P Butler; Sarah Edkins; Jenny M Andrews; Gemma Buck; Lina Chen; David Beare; Calli Latimer; Sara Widaa; Jonathon Hinton; Ciara Fahey; Beiyuan Fu; Sajani Swamy; Gillian L Dalgliesh; Bin T Teh; Panos Deloukas; Fengtang Yang; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962

9.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

10.  TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

Authors:  M-C Liang; J Ma; L Chen; P Kozlowski; W Qin; D Li; J Goto; T Shimamura; D N Hayes; M Meyerson; D J Kwiatkowski; K-K Wong
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more
  35 in total

1.  SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress.

Authors:  Takanori Nakamura; Haruo Saito; Mutsuhiro Takekawa
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

2.  Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.

Authors:  Emmet J Jordan; Olca Basturk; Jinru Shia; David S Klimstra; William Alago; Michael I D'Angelica; Ghassan K Abou-Alfa; Eileen M O'Reilly; Maeve A Lowery
Journal:  J Gastrointest Oncol       Date:  2017-10

3.  MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.

Authors:  Xiaozhen Wu; Zuode Gong; Lanying Sun; Long Ma; Qibao Wang
Journal:  Cell Prolif       Date:  2017-03-20       Impact factor: 6.831

4.  [Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].

Authors:  Shu Liu; Yi-Yi Liu; Rong Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

Review 5.  Molecular and pathophysiological aspects of metal ion uptake by the zinc transporter ZIP8 (SLC39A8).

Authors:  Zhong-Sheng Zang; Yan-Ming Xu; Andy T Y Lau
Journal:  Toxicol Res (Camb)       Date:  2016-02-18       Impact factor: 3.524

6.  Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.

Authors:  Yu Liu; Chong Chen; Zhengmin Xu; Claudio Scuoppo; Cory D Rillahan; Jianjiong Gao; Barbara Spitzer; Benedikt Bosbach; Edward R Kastenhuber; Timour Baslan; Sarah Ackermann; Lihua Cheng; Qingguo Wang; Ting Niu; Nikolaus Schultz; Ross L Levine; Alea A Mills; Scott W Lowe
Journal:  Nature       Date:  2016-03-16       Impact factor: 49.962

7.  Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors.

Authors:  T K Das; J Sangodkar; N Negre; G Narla; R L Cagan
Journal:  Oncogene       Date:  2012-08-13       Impact factor: 9.867

Review 8.  mTORC1 senses stresses: Coupling stress to proteostasis.

Authors:  Kuo-Hui Su; Chengkai Dai
Journal:  Bioessays       Date:  2017-03-15       Impact factor: 4.345

Review 9.  The 2 Faces of JNK Signaling in Cancer.

Authors:  Cathy Tournier
Journal:  Genes Cancer       Date:  2013-09

10.  Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.

Authors:  Anna A Marusiak; Natalie L Stephenson; Hayeon Baik; Eleanor W Trotter; Yaoyong Li; Karen Blyth; Susan Mason; Phil Chapman; Lorena A Puto; Jon A Read; Claire Brassington; Hannah K Pollard; Chris Phillips; Isabelle Green; Ross Overman; Matthew Collier; Ewelina Testoni; Crispin J Miller; Tony Hunter; Owen J Sansom; John Brognard
Journal:  Cancer Res       Date:  2015-12-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.